Ophthalmic device innovator BVI Medical has announced that the FDA has approved its FineVision HP trifocal intraocular lens (IOL). The approval allows the company to extend its reach in the IOL market.
The third-generation FineVision HP incorporates BVI’s proprietary POD platform and CoPODize technology, harmonising light distribution and minimising visual disturbances. The company says the double C-loop, four-point haptic design supports long-term stability and precise centration in the capsular bag.
The work of Christophe Pagnoulle, BVI R&D director, and ophthalmologist Damien Gatinel, M.D., Ph.D., brought the FineVision HP to market. The company says FineVision HP stands as the “world’s first” trifocal IOL.
U.S. surgeons and patients now gain access to this transformative lens, recognised globally for its patented diffractive optic design delivering balanced vision at far, intermediate and near distances.
“FineVision HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation,” said Shervin Korangy, President and CEO of BVI. “This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally.”
“The development of FineVision HP was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery,” said Dr. Damien Gatinel, developer and ophthalmologist. “FDA approval in the U.S. means even more patients will benefit from this breakthrough technology.”
“The FineVision HP trifocal IOL reflects innovation in optic design, and I’m pleased to have been part of the U.S. study evaluating its performance. This lens represents an important step forward in expanding advanced IOL choices for surgeons and their patients,” said Vance Thompson, M.D., ophthalmologist and study investigator.
Related
The post BVI Medical gains FDA approval for FineVision HP first appeared on TechToday.
This post originally appeared on TechToday.